Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
761 to 780 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Role of m6A Modifications in B-Cell Development and B-Cell-Related Diseases. | Int J Mol Sci | 2023 | 36902149 | PubTator, text mining | PubMed |
| Emerging Therapies in CLL in the Era of Precision Medicine. | Cancers (Basel) | 2023 | 36900373 | PubTator, text mining | PubMed |
| Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. | PLoS One | 2023 | 36897912 | PubTator, text mining | PubMed |
| Molecular profiling identifies at least 3 distinct types of posttransplant lymphoproliferative disorder involving the CNS. | Blood Adv | 2023 | 36897259 | PubTator, text mining | PubMed |
| Transformed Plasmablastic Lymphoma Presenting With Marked Lymphocytosis and Spontaneous Tumor Lysis Syndrome. | J Hematol | 2023 | 36895289 | PubTator, text mining | PubMed |
| Recombinant Insulin-Like Growth Factor 1 Dimers: Receptor Binding Affinities and Activation Abilities. | Int J Pept Res Ther | 2023 | 36891560 | PubTator, text mining | PubMed |
| Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy. | Biomark Res | 2023 | 36890557 | PubTator, text mining | PubMed |
| Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia. | Nat Commun | 2023 | 36890137 | PubTator, text mining | PubMed |
| Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma. | PLoS One | 2023 | 36888611 | PubTator, text mining | PubMed |
| Validation of Ligand Tetramers for the Detection of Antigen-Specific Lymphocytes. | J Immunol | 2023 | 36883850 | PubTator, text mining | PubMed |
| Plasma Cell Leukemia with Successful Upfront Venetoclax in Combination with Allogeneic Transplantation. | Am J Case Rep | 2023 | 36882990 | PubTator, text mining | PubMed |
| The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants. | Adv Clin Exp Med | 2023 | 36881367 | PubTator, text mining | PubMed |
| A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin. | Mol Ther Methods Clin Dev | 2023 | 36879849 | PubTator, text mining | PubMed |
| Characterization of clonal immunoglobulin heavy V-D-J gene rearrangements in Chinese patients with chronic lymphocytic leukemia: Clinical features and molecular profiles. | Front Oncol | 2023 | 36874132 | PubTator, text mining | PubMed |
| Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL. | Cancer Manag Res | 2023 | 36873252 | PubTator, text mining | PubMed |
| Screening of potential chemical marker with interspecific differences in Pterocarpus wood and a spatially-resolved approach to visualize the distribution of the characteristic markers. | Front Plant Sci | 2023 | 36866375 | PubTator, text mining | PubMed |
| Measurable residual disease in chronic lymphocytic leukemia. | Front Oncol | 2023 | 36865804 | PubTator, text mining | PubMed |
| The gene spectrum of thalassemia in Yangjiang of western Guangdong Province. | Front Genet | 2023 | 36861132 | PubTator, text mining | PubMed |
| The Outcomes of Diffuse Large B-cell Lymphoma Patients with Synchronous and Early Central Nervous System Involvement: A Single-Center Experience. | Asian Pac J Cancer Prev | 2023 | 36853313 | PubTator, text mining | PubMed |
| Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma. | Cancer Res | 2023 | 36853169 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=39